CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 1,845 enrolled
Drug / intervention
Estradiol +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01942668
NCT01942668Phase 3Completed
CompareCT.gov

A Phase 3 Study Safety and Efficacy Study of the Combination Estradiol and Progesterone to Treat Vasomotor Symptoms in Postmenopausal Women With an Intact Uterus

TherapeuticsMD·interventional·Posted Sep 16, 2013·Updated May 6, 2019

In Brief

A Phase 3 clinical trial evaluating Estradiol, Progesterone, and 1 other intervention for Menopause. Completed, enrolled 1,845 participants across 119 sites.

Detailed Summary

This study will be a prospective, randomized, double-blind, placebo-controlled, parallel group, multicenter trial of postmenopausal subjects with an intact uterus.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMenopause
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedSep 16, 2013
Enrollment StartAug 5, 2013
Primary CompletionOct 28, 2016
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 12.8 years ago

Interventions

Estradioldrug

Progesteronedrug

Placebodrug